Community

Advertising Opportunities

 Biotechnology Europe Programs

 Resources

Biotechnology Europe Community

Feedback

Contact

Biotechnology Europe Advantages

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

 

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe

Terms of Business

Imprint

Privacy Policy

FAQ

Subscribe Newsletter

 

  BIOTECHNOLOGY EUROPE NEWS    

 

 

 

 
 

   
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

post your news I subscribe newsletter I contact us

 
31.08.2010 Health Canada Grants Full Approval of Sativex For the Treatment of Spasticity Due to Multiple Sclerosis  
GW Pharmaceuticals (AIM: GWP) and Bayer Inc., a subsidiary of Bayer AG, today announced that Health Canada has approved Sativex® [delta-9-tetrahydrocannabinol 27 mg/mL (from Tetrabinex® - cannabis sativa L. extract) and cannabidiol 25 mg/mL (from Nabidiolex® - cannabis sativa L. extract)] as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS). Sativex® is the first cannabinoid medicine derived from whole plant extracts from the cannabis sativa plant containing both delta-9-tetrahydrocannabinol and cannabidiol. This means that people in Canada with MS experiencing the debilitating symptoms of spasticity, such as painful spasms and cramps, will now have a new treatment option in addition to standard therapy. 
   
 
31.08.2010 Vetter Opens New Sales Office at Illinois Science + Technology Park in Suburban Chicago  
In keeping with its strategy of U.S. growth and expansion, Vetter, a specialist in aseptically prefilled drug-delivery systems, today announced that it has opened a new sales office at the Illinois Science +Technology Park in Skokie. The office will be managed by Mr. Troy Carpenter, who was appointed as President of Vetter Pharma International USA Inc. The new office replaces its Yardley, Pennsylvania sales office, founded in 1983 as Vetter Pharma-Turm Inc. The establishment of the new office in the Midwest region, considered an emerging “hotspot” in biotechnology, is consistent with the company’s stated objective for worldwide growth by focusing on the emerging pharmaceutical and biotechnology market in North America. The office, to be officially known as Vetter Pharma International USA Inc., is a wholly owned subsidiary of Vetter Pharma International GmbH, which is responsible for Vetter’s sales and marketing as well as customer service functions. In 2009, Vetter announced the creation of its first U.S. manufacturing facility, also located at the Illinois Science + Technology Park. The facility – an expansion of Vetter Development Service – is scheduled to be operational in the beginning of the fourth quarter of 2010.
   
 
25.08.2010 Brookwood International Academy And Argint International Announce Strategic Partnership  
Argint International (“Argint”), a clinical research organisation based in Central and South-Eastern Europe, and Brookwood International Academy (“the Academy”), an independent academy specialising in clinical research and Good Clinical Practice (GCP) training and certification based in Guildford, UK, have entered into a strategic partnership. Under the terms of the agreement, Argint obtains exclusive distribution rights for the Academy’s training courses throughout Central and South Eastern Europe (CEE/SEE). 
   
 
24.08.2010 Oxford BioMedica plc: Interim Results for the Six Months Ended 30 June 2010  
Oxford Biomedica (“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene therapy company, today announces its unaudited interim results for the six months ended 30 June 2010. Year to date highlights include:
   
 
20.08.2010 Putting the patient first: students work with elderly to define the next stage of the connected health revolution  
Cambridge Consultants, a leading technology product design and development firm, today shared recommendations on how to increase adoption of new connected health technologies that will help to improve wellness among the nation's growing elderly population. The findings were based on field research conducted by students from the Tufts University School of Engineering and individual interviews with elderly patients and their healthcare providers.
   
 
18.08.2010 CEVEC Signs Global License Agreement for Human CAP-T Technology with Life Technologies  
CEVEC Pharmaceuticals, the developer of a novel human protein expression system derived from amniocytes, announced today the signing of a co-exclusive worldwide licensing agreement with Life Technologies Corporation, a leading provider of innovative life science solutions based in Carlsbad, California. Under the terms of the agreement, Life Technologies and CEVEC will co-operate to offer optimized expression kits based on CEVEC’s proprietary CAP-T cells to the global life science research community. Life Technologies will pay CEVEC a signing fee and various milestone payments and royalties on sales of the future products. Further details of the agreement were not disclosed. CEVEC will continue to expand its global license business of the CAP® and CAP-T® technologies for commercial use and industrial development purposes.
   
 
18.08.2010 Oxford BioMedica Announces Licensing Agreement with Emergent BioSolutions Inc.  
Oxford Biomedica (“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene therapy company, today announces that it has signed a licensing agreement with Emergent Product Development Germany GmbH (“Emergent”), a wholly-owned subsidiary of Emergent BioSolutions Inc. The agreement grants Emergent non-exclusive rights to Oxford BioMedica’s Hi-8® PrimeBoost technology patents and a sub-licence under poxvirus patents licensed to the Company for the development and commercialisation of vaccines and therapeutics targeting eight infectious diseases, including Tuberculosis.
   
 
16.08.2010 New Isolera™ UV-VIS Flash Purification System Delivers Widest Wavelength Range Available to Chemists  
Biotage (STO: BIOT), a leading developer of tools and technology for medicinal and analytical chemistry, announces the introduction of the Isolera™ UV-VIS flash purification system. The UV-VIS system enables detection of organic molecules with spectral absorbance between 200 nm and 800 nm making it the broadest wavelength detection flash system available to chemists. The system provides detection capable to near IR range. Applications for the UV-VIS system include natural products (carotenoids, flavanoids, proanthocyanidins, etc.), synthetic dyes, diagnostic dyes, and OLED chemicals.
   
 
13.08.2010 Axis-Shield Welcomes Formal Approval of Anti-CCP Antibody Testing for Diagnosis of Early Rheumatoid Arthritis  
Axis-Shield (LSE:ASD, OSE:ASD),  the international in vitro diagnostics company, today welcomes the publication of new classification criteria for rheumatoid arthritis (RA) in the September 2010 edition of “Arthritis and Rheumatism” Vol. 62, No. 9, pp 2569– 2581, by Aletaha et al. The revised criteria have been approved by the American College of Rheumatology (ACR) Board of Directors and the European League Against Rheumatism (EULAR) Executive Committee, signifying that the criteria set has been quantitatively validated using patient data, and it has undergone validation based on an external data set.
   
 
10.08.2010 Anavex Appoints Contract Research Organizations to Initiate Phase I/IIa Clinical Programs, Regulatory Strategies in Alzheimer’s Disease  
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today announced that it has signed a definitive master services agreement with Genesis BioPharma Group (“Genesis”) and ABX-CRO Advanced Pharmaceutical Services (“ABX-CRO”) to begin clinical studies and regulatory filings  for ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s Disease.
   
 
09.08.2010 Myconostica Announces CE Marking of MycAssay™ Product Family on Additional Platforms  
Myconostica Ltd, the UK-based medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today announces the CE marking of its lead products MycAssay™ Aspergillus and MycAssay™ Pneumocystis on the Roche Lightcycler® 2.0 and Stratagene Mx3000 series platforms.
   
 
05.08.2010 MediGene AG Reports Financial Results for First Six Months of 2010: Continuing Increase in Total Revenue, Significant Reduction of Loss  
In the first six months of 2010, the biotech company MediGene AG (Frankfurt, Prime Standard, TecDAX) increased total revenue by 26% to EUR 25.2 million, and reduced the loss on an EBITDA basis by 20% to EUR -5.4 million. The net loss was reduced by 60% to EUR -3.3 million. These results are reported in compliance with IFRS (International Financial Reporting Standards).
   
 
06.08.2010 TEMPO study further demonstrates the benefits of Azilect® in early Parkinson's disease patients  
H.Lundbeck A/S and Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced newly published long-term data on Azilect® (rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson's disease (PD) and further demonstrate the benefits obtained with early treatment initiation. The data was published in the June 2010 issue of the International Journal of Neuroscience.
   
 
04.08.2010 Glycotope Received Regulatory Approval for Glycooptimized and Fully Human Glycosylated Antibody CetuGEX™ and Enrolls First Patients in Clinical Trial  
Glycotope GmbH, a leading glycobiology company, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope´s next generation antibody CetuGEX™ (GT-MAB 5.2-GEX) for the treatment of various solid cancers.
   
 
02.08.2010 MorphoSys Announces Clinical Milestone from Strategic Alliance  
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it will receive a milestone payment from Novartis in connection with the initiation of a phase 1 clinical trial of a HuCAL-derived, fully human antibody in the therapeutic area of ophthalmology. Today's news marks the entry of the third HuCAL-derived antibody into human clinical trials in 2010, following the advancement of one program each from the alliances with Novartis and Centocor Ortho Biotech earlier this year.
   
   
 
 I back I top I  

                                                                

office@biotechnology-europe.com I website@biotechnology-europe.com I service@biotechnology-europe.com

 


 

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

About Biotechnology Europe

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe


 

Biotechnology Europe Your Partner in Bioscience and Business

  Central Internet Platform and Service Company For The Life Sciences in Europe

Imprint I Site map I Privacy Policy I Contact us I About us I Copyright BIOTECHNOLOGY WORLD  All rights reserved